Kastle Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-07-16
- Employees
- 11
- Market Cap
- -
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Phase 3
Completed
- Conditions
- Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsHyperlipoproteinemiasDyslipidemiasHypercholesterolemia, Autosomal DominantMetabolic DiseasesHyperlipoproteinemia Type IIGenetic Diseases, InbornInfant, Newborn, DiseasesMetabolic Disorder
- Interventions
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT00694109
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- Metabolic DiseasesHypercholesterolemiaHyperlipidemiasMetabolism, Inborn ErrorsMetabolic DisorderHyperlipoproteinemiasDyslipidemiasLipid Metabolism, Inborn ErrorsGenetic Diseases, InbornInfant, Newborn, Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00607373
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Phase 2
Completed
- Conditions
- Lipid Metabolism, Inborn ErrorsMetabolic DiseasesHypercholesterolemia, Autosomal DominantHyperlipidemiasInfant, Newborn, DiseasesHyperlipoproteinemia Type IIGenetic Diseases, InbornMetabolic DisorderCongenital AbnormalitiesHypercholesterolemia
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT00477594
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
Phase 2
Completed
- Conditions
- Metabolism, Inborn ErrorsGenetic Diseases, InbornCongenital AbnormalitiesMetabolic DisorderHypercholesterolemiaHyperlipidemiasMetabolic DiseasesHypolipoproteinemiasLipid Metabolism DisordersLipid Metabolism, Inborn Errors
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00362180
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00280995
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
Phase 2
Completed
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- Drug: ISIS 301012 or Placebo
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00281008
Dose-escalating Safety Study in Subjects on Stable Statin Therapy
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: ISIS 301012 or Placebo
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT00231569
Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: ISIS 301012 or Placebo
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00216463
© Copyright 2025. All Rights Reserved by MedPath